Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05022147 · ClinicalTrials.gov registry record · Phase 1
Enhancing Gait Using Alternating-Frequency DBS in Parkinson Disease
A Phase 1 study of Parkinson Disease and Deep Brain Stimulation, sponsored by James Liao.
- Active
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
- 1
- Study location
NCT05022147: Active Phase 1 study of Parkinson Disease and Deep Brain Stimulation, sponsored by James Liao.
NCT05022147 is a Phase 1 study of Parkinson Disease and Deep Brain Stimulation that is active but no longer recruiting, run by James Liao. The registered enrollment target is 12 participants, below the 5,326-participant average among 297 other Parkinson Disease trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05022147, a Phase 1 study of Parkinson Disease and Deep Brain Stimulation, is active but no longer recruiting, sponsored by James Liao.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to assess how alternating-frequency Deep Brain Stimulation (DBS) works to improve postural instability and gait, while also treating other motor symptoms of Parkinson Disease (PD).
Primary Outcome
Marker of gait instability, derived from kinematic recordings from body-worn wireless sensors.
Conditions Studied
Interventions
- DEVICE High-Frequency-Only Stimulation
- DEVICE Low-Frequency-Only Stimulation
- DEVICE Alternating, 50 sec High-Frequency, 10 sec Low-Frequency Stimulation
- DEVICE Alternating, 50 sec High-Frequency, 50 sec Low-Frequency Stimulation
- DEVICE Alternating, 10 sec High-Frequency, 50 sec Low-Frequency Stimulation
Study Locations (1)
Ohio
- Cleveland Clinic Foundation - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2021-10-04 |
| Est. Completion | 2026-05 |
| Phase | Phase 1 |
What the registry record for NCT05022147 still lists
NCT05022147 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 12 participants, a relatively small participant target, below the 5,326-participant average among 297 other Parkinson Disease trials with a reported enrollment target (100% lower).
The record links to 6 conditions, with Parkinson Disease appearing as the primary indexed condition, and to 5 interventions - of which High-Frequency-Only Stimulation is the first listed.
NCT05022147 reports a single indexed study location in Ohio.
Frequently Asked Questions
What is clinical trial NCT05022147 about?
NCT05022147 is a clinical study titled "Enhancing Gait Using Alternating-Frequency DBS in Parkinson Disease". The purpose of this study is to assess how alternating-frequency Deep Brain Stimulation (DBS) works to improve postural instability and gait, while also treating other motor symptoms of Parkinson Disease (PD).
What is the current status of trial NCT05022147?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2021-10-04. Estimated completion is 2026-05.
What conditions does trial NCT05022147 study?
This clinical trial studies the following conditions: Parkinson Disease, Deep Brain Stimulation, Accidental Fall, Gait Disorders, Neurologic, Disease Progression.
What interventions are being tested in trial NCT05022147?
The interventions under investigation include: High-Frequency-Only Stimulation (DEVICE), Low-Frequency-Only Stimulation (DEVICE), Alternating, 50 sec High-Frequency, 10 sec Low-Frequency Stimulation (DEVICE), Alternating, 50 sec High-Frequency, 50 sec Low-Frequency Stimulation (DEVICE), Alternating, 10 sec High-Frequency, 50 sec Low-Frequency Stimulation (DEVICE).
Who is sponsoring clinical trial NCT05022147?
This trial is sponsored by James Liao, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05022147 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Parkinson Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05022147's enrollment target sits among peer trials
12 268th of 297 higher than 24 of 297 other Parkinson Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Parkinson Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of LY4006896 in Healthy Participants and Participants With Parkinson's Disease
RECRUITING · Phase 1
-
Treating Parkinson's Disease Through Transplantation of Autologous Stem Cell-Derived Dopaminergic Neurons
RECRUITING · Phase 1
-
First-in-Human Single and Multiple Dose of HL-400
RECRUITING · Phase 1
-
Phase 2 Trial of Tributyrin in People With Parkinson's Disease and Cognitive Impairments
RECRUITING · Phase 1
-
[18F]F-DOPA Imaging in Patients With Autonomic Failure
RECRUITING · Phase 1
-
A Study to Assess the Safety of BMS-984923 Compared to Placebo, in People With Parkinson's
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02602769 · 12 participants
Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome
- NCT02605421 · 12 participants · Phase 2
Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma
- NCT02619448 · 12 participants · Early Phase 1
Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC
- NCT03311503 · 12 participants · Phase 1
Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI